Welcome to our dedicated page for Kala Pharmaceuticals news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on Kala Pharmaceuticals stock.
Kala Pharmaceuticals Inc (NASDAQ: KALA) is a clinical-stage biopharmaceutical company pioneering novel therapies for severe ocular diseases through its proprietary MSC-S platform and nanoparticle drug formulations. This page provides authorized updates on KALA's clinical developments, regulatory milestones, and research advancements.
Investors and researchers will find verified press releases covering Phase 2/3 trial progress for lead candidate KPI-012 in PCED treatment, FDA designations for rare disease therapies, and peer-reviewed study publications. All content is curated to meet strict journalistic standards for accuracy in biopharmaceutical reporting.
The news archive includes updates on corneal healing therapies, retinal disorder research collaborations, intellectual property developments, and scientific conference presentations. Content is organized chronologically with clear sourcing to enable efficient tracking of the company's progress in ocular regenerative medicine.
Bookmark this page for direct access to Kala Pharmaceuticals' official announcements, including trial enrollment updates, partnership disclosures with academic institutions, and manufacturing scale-up progress. Check regularly for the latest validated information on this innovative developer of first-in-class ocular biologics.
KALA BIO reported its Q4 and full year 2024 financial results, highlighting progress in its Phase 2b CHASE trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED). The company has randomized 87 patients and expects topline data in Q3 2025.
Key financial highlights include:
- Raised $10.75 million in private placement financing
- Cash position of $51.2 million as of December 31, 2024
- Q4 2024 net loss of $8.2 million ($1.74 per share)
- Full year 2024 net loss of $38.5 million ($10.15 per share)
The company's cash runway extends into Q1 2026. KALA's lead product candidate, KPI-012, targets PCED, which affects approximately 100,000 patients in the U.S. The CHASE trial could potentially serve as the first of two pivotal studies required for FDA approval.
KALA BIO (NASDAQ: KALA), a clinical-stage biopharmaceutical company focused on developing innovative eye disease therapies, has announced its participation in the TD Cowen 45th Annual Health Care Conference. The presentation is scheduled for March 5, 2025, at 11:50 a.m. ET in Boston, MA.
The company's management team will deliver the presentation and will be available for one-on-one meetings throughout the day. Interested parties can access the webcast and subsequent recording through the 'Presentations' section on www.kalarx.com.
KALA BIO (NASDAQ:KALA) announced a leadership transition with CEO Mark Iwicki stepping down and Todd Bazemore, the company's President and Chief Operating Officer, appointed as interim CEO, effective immediately. Iwicki will continue as Chair of the Board of Directors.
Bazemore, who has served as KALA's President since December 2021 and COO since November 2017, brings over 30 years of experience in the pharmaceutical industry. The transition comes as the company approaches topline data from its Phase 2b clinical trial of KPI-012 for PCED (Persistent Corneal Epithelial Defect) in the second quarter of 2025.
Prior to KALA, Bazemore held executive positions at Santhera Pharmaceuticals, Dyax Corp, and Sunovion Pharmaceuticals. The company continues to focus on developing innovative therapies for rare and severe eye diseases using its MSC-S platform.
KALA BIO has secured a $10.75 million private placement through the sale of common stock and Series I Convertible Non-Redeemable Preferred Stock to institutional investors, including SR One, Cormorant Asset Management, and Woodline Partners. The company will sell 1,340,603 common shares at $6.44 per share and 3,286 preferred shares at $644.00 per share.
The funding, expected to close by December 31, 2024, will extend KALA's operations into Q1 2026. Proceeds will support the clinical development of KPI-012 for persistent corneal epithelial defect. The CHASE trial has achieved over 80% enrollment across 40+ clinical sites, with topline data expected in Q2 2025.
KALA BIO (NASDAQ:KALA) has announced its participation in the Piper Sandler 36th Annual Healthcare Conference in New York. Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer, will deliver a presentation on December 4, 2024, at 11:30 a.m. ET. The company, which focuses on developing innovative therapies for rare and severe eye diseases, will also be available for one-on-one meetings during the conference. A webcast of the presentation will be accessible through the 'Presentations' section on KALA's website.
KALA BIO reported Q3 2024 financial results and provided updates on its Phase 2b CHASE trial of KPI-012 for Persistent Corneal Epithelial Defect (PCED). The company reported cash and equivalents of $49.2 million as of September 30, 2024, expecting to fund operations into Q4 2025. Q3 net loss was $9.0 million ($1.93 per share), compared to $8.7 million in Q3 2023. The company initiated five clinical trial sites in Argentina and expects topline results from the CHASE trial in Q2 2025. KPI-012 aims to be a first-in-class treatment for PCED, targeting an estimated U.S. market of 100,000 patients.
KALA BIO (NASDAQ:KALA), a clinical-stage biopharmaceutical company focused on innovative therapies for rare and severe eye diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer, will deliver a pre-recorded presentation available from August 15, 2024, at 7:00 a.m. ET.
The company's management team will also be available for virtual one-on-one meetings throughout the conference. Interested parties can access the webcast and subsequent recording of the presentation through the 'Presentations' section of KALA BIO's website at www.kalarx.com.
KALA BIO (NASDAQ:KALA) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Closed a $12.5 million private placement financing
- Cash resources of $54.2 million as of June 30, 2024
- Funding expected to last into Q4 2025
- Topline data from Phase 2b CHASE trial of KPI-012 for PCED targeted in Q1 2025
The company is advancing its MSC-S platform technology, focusing on KPI-012 for PCED and exploring potential in other eye diseases. Q2 2024 financial results show a net loss of $9.6 million, or $3.16 per share, compared to $10.4 million, or $4.36 per share, in Q2 2023.
KALA BIO, a clinical-stage biopharmaceutical company, announced a private placement agreement with institutional investors to sell 1,197,314 shares of common stock at $5.85 per share and 9,393 shares of Series H Preferred Stock at $585.00 per share, raising approximately $12.5 million before expenses.
The placement, led by SR One with participation from ADAR1 Capital Management and another life sciences-focused investor, is set to close around June 28, 2024, pending customary conditions. Net proceeds will fund the clinical development of KPI-012 for persistent corneal epithelial defects and general corporate purposes.
The securities are unregistered under the Securities Act of 1933 and will only be offered via a prospectus. KALA will file a registration statement with the SEC within 30 days post-closing for resale purposes.
KALA BIO (NASDAQ:KALA) will present at the Jefferies Global Healthcare Conference on June 5, 2024, in New York, NY. Kim Brazzell, Ph.D., Head of R&D and Chief Medical Officer, will deliver the presentation at 12:30 p.m. ET. The company's management team is also available for one-on-one meetings on the same day. The presentation's webcast and archived recording will be accessible on the KALA website.
FAQ
What is the current stock price of Kala Pharmaceuticals (KALA)?
What is the market cap of Kala Pharmaceuticals (KALA)?
